Abstract 4446
Background
Standard of care of high grade glia tumors is represented by concomitant temozolomide (TMZ) and radiotherapy (RT), followed by maintenance TMZ. In clinical practice, administering the full programmed cumulative dose of treatment is often a challenge. The effect of different cumulative doses of maintenance TMZ on median overall survival (mOS) is yet not known.
Methods
We retrospectively analyzed patients with histological diagnosis of high grade glia tumors (91% grade IV, 7% grade III, 2% others) treated at our institution with RT plus concomitant TMZ, followed by maintenance TMZ (according to the trial by Stupp et al.), between February 2012 and April 2019. We planned 6 cycles of maintenance TMZ in patients without MGMT hypermethylation and 12 cycles in those with MGMT hypermethylation. The main objective of our research was to study the effect of cumulative dose of maintenance TMZ on mOS in patients without MGMT hypermethylation. We also focused on time from diagnosis to beginning of chemoradiotherapy and its potential effect on mOS in our whole cohort. We performed statistical analysis with SPSS, using Kaplan-Meier curves.
Results
We enrolled 114 patients, with median age of 63 years (IQR 54-69 y). MGMT was hypermethylated in 35 (30%) patients, not hypermethylated in 56 (49%) patients, unknown in 24 (21%) patients. In our cohort, mOS was 14 months, in line with previously reported data. In patients without MGMT hypermethylation, mOS was 23,4 months when cumulative dose of maintenance TMZ was > = 4500 mg/m2 versus 11 months when cumulative dose was < 4500 mg/m2(HR 0,23 [0,10-0,54, CI 95%], p < 0,001). When considering our entire cohort, chemoradiotherapy was started in a median of 44 days from diagnosis (IQR 35-56 days); mOS was not statistically different in patients who started therapy over 42 days after diagnosis (HR 0,76 [0,44-1,33, CI 95%], p 0,35).
Conclusions
Our study shows that in patients with high grade glia tumors without MGMT hypermethylation a cumulative dose of maintenance TMZ < 4500 mg/m2negatively impacts on mOS compared to a cumulative dose of > = 4500 mg/m2. Moreover time elapsed from diagnosis to beginning of treatment does not significantly influence mOS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, ASST-Settelaghi, Varese (Italy).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract